Therapeutic Expertise

Haematology (Sickle Cell Disease & Other Blood Disorders)

Transforming Rare Disease Research in Africa

Sub-Saharan Africa bears nearly 75% of the global burden of Sickle Cell Disease (SCD), with over 300,000 infants born each year with the condition most without access to early screening or disease-modifying therapies. Beyond SCD, the region faces a high prevalence of anemia, hemophilia, thalassemia, and other inherited or acquired hematologic disorders, representing a critical frontier for innovation in precision medicine and global health equity.

At Xcene Research, we are pioneering hematology research in Africa with a focus on Sickle Cell Disease and other rare blood disorders, serving as a strategic partner for global sponsors, biopharma companies, and academic institutions. Having conducted more than eight multi-country SCD clinical trials across Nigeria, Ghana, Kenya, Uganda, and Zambia, Xcene Research has established the largest operational sickle cell and hematology trial network in Sub-Saharan Africa, integrating clinical excellence, patient advocacy, and translational research capabilities.

Capabilities

• Clinical Trials in SCD, Anemia, and Coagulation Disorders
  Full-service management of interventional and observational studies investigating disease-modifying agents, cell& gene therapies, biologics, and small molecules for sickle cell, thalassemia, and bleeding disorders.
• Advanced Gene and Cell Therapy Trials
  Expertise in supporting CRISPR-based, lentiviral, and ex vivo gene-modified cell therapy protocols, including long-term follow-up studies aligned with international biosafety and GCP requirements.
• Integrated Laboratory and Genomic Infrastructure
  Access to ISO 15189 and CAP-ready laboratories for genotyping, biomarker monitoring, and pharmacovigilance, with advanced platforms for molecular diagnostics, next-generation sequencing, and hematologic assay validation.
• Real-World Data and Digital Patient Monitoring
  Use of Genescor, our digital health ecosystem, for longitudinal patient tracking, remote adherence monitoring, and symptom management in chronic and rare disease cohorts.
• Community and Advocacy Partnerships
  Deep collaboration with regional SCD foundations, patient advocacy organizations, and tertiary hospitals to enhance patient recruitment, education, and retention ensuring community-centered, ethical, and inclusive research.

Our Differentiation

• Africa’s Largest Sickle Cell Disease Trial Network Across SSA
  Multi-country footprint with harmonized regulatory, operational, and ethical frameworks that enable rapid study start-up and scalable trial delivery.
• Unmatched Recruitment and Retention in Rare Disease Populations
  Proven strategies for engaging and sustaining participation in long-duration studies, including pediatric and adolescent populations.
• Cultural and Linguistic Fluency
  Culturally tailored patient engagement and education programs delivered in multiple local languages through digital and in-person channels.
• Translational Science Integration
  Seamless linkage between clinical and laboratory operations from biomarker discovery to pharmacogenomics and therapeutic monitoring ensuring that every trial contributes to real-world understanding of disease biology.
• Collaborative Research Ecosystem
  Strategic partnerships with global biopharma, gene therapy developers, and academic hematology centers to drive innovation from bench to bedside.

We combine world-class scientific rigor with local insight to transform the landscape of hematology and rare disease research in Africa. Through our work, millions of individuals affected by blood disorders gain access to cutting-edge therapies, genetic screening, and holistic care models bridging the gap between innovation and equity in global health.

Driving Cardiovascular Innovation with Precision and Reach

Cardiovascular diseases (CVDs) remain the leading cause of adult mortality in Africa, accounting for over 20% of all deaths and representing a growing burden linked to urbanization, metabolic risk factors, and limited access to early diagnostic care. In response, Xcene Research has built one of the most extensive cardiovascular research networks in Sub-Saharan Africa — enabling the design, execution, and oversight of clinical studies that advance equitable access to life-saving cardiovascular innovations.

Through our Cardiovascular Therapeutic Network, encompassing more than 40 principal investigators and 18 cardiology and internal medicine research centers, we support sponsors in evaluating novel therapeutics, diagnostics, and digital interventions in diverse, real-world African populations. Our infrastructure integrates hospital-based trial units, outpatient clinics, and telehealth platforms to facilitate continuous follow-up, robust data collection, and patient retention.

Capabilities

• Interventional and Observational Trials (Phase II–IV)
  Full-service management of multicenter trials focused on hypertension, heart failure, atherosclerosis, dyslipidemia, arrhythmias, and thromboembolic disorders, including drug, biologic, and device-based therapies.
• Biomarker-Driven and Precision Medicine Approaches
  Study designs incorporating genetic, proteomic, and metabolomic biomarkers to refine patient stratification, evaluate therapeutic response, and identify population-specific cardiovascular risk signatures.
• Advanced Cardiac Safety and Endpoint Validation
  Centralized monitoring of ECG, echocardiography, troponin, BNP, and other biomarkers to support cardiac safety evaluation in both early- and late-phase studies.
• Digital Health & Remote Monitoring Integration
  Deployment of wearable sensors, home BP monitoring, and connected cardiac devices integrated with mobile platforms for real-time data capture, improving adherence and reducing follow-up losses.
• XP Recruiter for Patient Identification and Retention
  Proprietary digital recruitment platform that leverages electronic health data and community-based outreach to identify eligible participants and maintain engagement throughout study duration.
• Hybrid Telehealth & Home-Visit Models
  Implementation of decentralized follow-up strategies including nurse-led home visits and teleconsultations minimizing participant travel and optimizing retention in long-duration cardiovascular trials.

Our Differentiation

We conduct cardiovascular research with precision, integrity, and agility, ensuring that Africa’s cardiovascular data informs global innovation. By bridging world-class scientific standards with regional expertise and patient-centered engagement, Xcene Research empowers sponsors and investigators to deliver the next generation of heart therapies — where every data point represents a life impacted.

Expanding Access to Cancer Innovation in Africa

Cancer remains one of the fastest-growing health burdens across Sub-Saharan Africa, with incidence rates projected to double by 2040. Despite remarkable advances in cancer therapeutics worldwide, limited access to early diagnosis, biomarker testing, and clinical trial opportunities continues to impede progress on the continent.

Xcene Research is closing this gap through its Oncology Therapeutic Network — a continent-wide consortium of more than 30 oncologists, 10 pathology-equipped hospitals, and regional research partners dedicated to expanding cancer innovation and equitable access to advanced therapies in Africa. Our network enables sponsors to evaluate next-generation immunotherapies, targeted agents, and diagnostics across breast, cervical, prostate, hematologic, and solid tumor indications, ensuring that African patients are meaningfully represented in global oncology research.

Capabilities

• Early- and Late-Phase Oncology Trials
  End-to-end management of Phase I–IV interventional and observational studies, including dose-escalation, safety, and efficacy trials in solid and hematologic malignancies. Expertise spans chemotherapy, targeted therapy, checkpoint inhibitors, antibody-drug conjugates (ADCs), and cell-based immunotherapies.
• Tumor Biopsy, Histopathology, and Biomarker Analysis
  Integration with central pathology and molecular laboratories for tissue processing, immunohistochemistry, next-generation sequencing (NGS), and liquid biopsy assays, enabling biomarker-driven trial design and stratified enrollment.
• Precision Oncology and Genomic Profiling
  Capacity for somatic and germline variant analysis, including BRCA, EGFR, ALK, KRAS, and PD-L1 testing, with secure data integration into study-specific bioinformatics platforms.
• Imaging and Digital Data Systems
  Deployment of cloud-based imaging repositories and oncology EDC/CTMS systems supporting RECIST 1.1 evaluation, radiologic endpoint adjudication, and cross-site data harmonization.
• Patient Recruitment and Survivorship Engagement
  Use of XP Recruiter to identify eligible oncology patients through hospital databases and advocacy networks, coupled with Genescor-enabled digital follow-up and survivorship support tools for sustained engagement.

Our Differentiation

• Pan-African Oncology Network
  Multidisciplinary collaboration among oncologists, pathologists, radiologists, and data scientists with rapid-response site start-up capability across major cancer centers in Nigeria, Ghana, Kenya, and South Africa.
• Molecular and Genomic Readiness
  Access to advanced genomic and molecular profiling platforms supporting precision oncology and pharmacogenomic studies in collaboration with global bioinformatics partners.
• Regulatory and Ethical Excellence
  Proven track record in navigating complex oncology approvals through alignment with ICH-GCP, local ethics committees, and international oncology regulatory frameworks.
• Community and Registry Partnerships
  Established collaborations with cancer registries, advocacy organizations, and screening programs to enhance early detection, trial enrollment, and population-specific cancer data.
• Diversity and Inclusion Leadership
  Commitment to ensuring African genetic and clinical diversity informs global oncology development, driving equity in therapeutic access and translational research outcomes.

We are redefining oncology research in Africa by merging precision medicine with population diversity. Through scientific rigor, operational excellence, and community trust, Xcene Research is enabling global sponsors to develop and validate cancer therapies that reflect the true genetic and clinical diversity of humanity transforming how cancer is studied, treated, and cured across the continent.

Delivering End-to-End Vaccine Studies from Feasibility to Implementation

Africa stands at the frontier of global vaccine innovation both as a region of high disease burden and as a critical hub for clinical advancement. With decades of experience in infectious disease and community-based research, Xcene Research enables the design and delivery of end-to-end vaccine studies that meet the highest international standards of safety, efficacy, and ethics while responding to local realities.

Our Vaccine Research Network spans public health institutions, community clinics, tertiary hospitals, and cold-chain–equipped laboratories across Sub-Saharan Africa. This infrastructure allows us to execute feasibility assessments, Phase I–IV clinical trials, immunogenicity testing, and post-marketing surveillance for both novel and established vaccines. We operate with a mission to ensure that Africa not only benefits from but also contributes meaningfully to global immunization innovation.

Capabilities

• Comprehensive Vaccine Development Support (Phase I–IV)
  Full-service management of early- and late-phase trials, including first-in-human (FIH), maternal, pediatric, and booster vaccine studies. Our teams are adept at supporting viral vector, mRNA, subunit, conjugate, and live-attenuated platforms, ensuring robust trial design and execution from dose-ranging to large-scale efficacy studies.
• Feasibility and Site Readiness Mapping
  Data-driven assessment of urban and rural communities for epidemiologic suitability, infrastructure capacity, and demographic diversity. Our readiness framework ensures that every participating site meets WHO, ICH-GCP, and national ethics standards before initiation.
• Integrated Immunology and Serology Laboratories
  Access to centralized CAP/ISO 15189-accredited laboratories with validated platforms for immunogenicity, neutralizing antibody titers, ELISA, qPCR, and molecular assays. We also provide sample logistics, cold-chain management, and real-time electronic data capture for laboratory endpoints.
• Cold-Chain and Logistics Management
  End-to-end support for vaccine storage, handling, and distribution with temperature-controlled systems and real-time tracking for temperature excursions. Our logistics partners are qualified for Good Distribution Practice (GDP) compliance, ensuring product integrity from importation to site-level administration.
• Pharmacovigilance and Safety Monitoring
  Dedicated safety teams monitor adverse events following immunization (AEFI) and serious adverse events (SAEs) through centralized pharmacovigilance systems integrated with electronic CRFs and national reporting frameworks.
• Community Engagement and Ethical Enrollment
  Implementation of community sensitization campaigns, stakeholder mapping, and culturally tailored consent processes to ensure participant understanding, ethical integrity, and sustained engagement.
• Post-Marketing and Effectiveness Studies
  Execution of Phase IV, observational, and real-world evidence (RWE) studies to evaluate long-term safety, effectiveness, and population-level impact, including vaccine hesitancy and uptake behavior research.

Our Differentiation

Xcene Research delivers vaccine studies that embody scientific precision, operational excellence, and community trust. By integrating cutting-edge laboratory science, regulatory fluency, and deep local engagement, we ensure that Africa remains not just a site of study, but a driving force in global vaccine discovery and implementation.

Through our work, we bridge continents and disciplines empowering governments, sponsors, and global partners to build an equitable and resilient immunization future.

Advancing Kidney Health Research with Precision and Compassion

Chronic Kidney Disease (CKD) affects an estimated 15–20% of adults in Sub-Saharan Africa, with a disproportionate impact driven by hypertension, diabetes, infections, and genetic susceptibility. Despite its growing prevalence, early diagnosis and access to renal replacement therapies remain limited, underscoring the urgent need for inclusive, regionally grounded nephrology research.

Xcene Research brings efficiency, empathy, and scientific accuracy to kidney-health innovation through a continent-wide network of 20+ nephrologists and multiple dialysis and transplant centers. Our Nephrology Therapeutic Network partners with tertiary hospitals and teaching institutions to conduct early- and late-phase clinical trials addressing CKD, diabetic nephropathy, dialysis outcomes, and transplant medicine, ensuring that Africa’s renal disease burden is reflected in global data and therapeutic development.

Capabilities

• Clinical Studies Across the Kidney Disease Continuum
  Comprehensive management of Phase II–IV trials investigating novel therapies for CKD progression, diabetic nephropathy, acute kidney injury, hemodialysis optimization, and post-transplant immunomodulation.
• Electronic Renal Data and Biomarker Tracking
  Real-time monitoring of eGFR, serum creatinine, cystatin C, proteinuria, and novel renal biomarkers via integrated electronic data capture systems for longitudinal renal function analysis.
• Digital Patient Identification and Cohort Mapping
  Use of XP Recruiter and hospital registry integration to identify eligible CKD patients, dialysis participants, and comorbid individuals (hypertension, diabetes, or cardiovascular risk), enhancing recruitment accuracy and efficiency.
• Remote Monitoring and Teleconsultation
  Deployment of telehealth models and mobile-based follow-up to reduce participant burden, ensure continuity of care, and enable decentralized renal research in rural and urban populations.
• Translational and Device Studies
  Experience in supporting renal device evaluations (e.g., hemodialysis machines, catheters, filtration technologies) and biologic or regenerative trials exploring innovative pathways in renal replacement and tissue recovery.

Our Differentiation

• Integrated Nephrology Trial Management
  End-to-end clinical and operational support guided by nephrology specialists — from feasibility and site activation to monitoring and regulatory reporting.
• Regulatory and Safety Expertise
  Deep familiarity with renal-specific pharmacovigilance, device trial oversight, and safety monitoring in collaboration with national ethics bodies and regulatory agencies.
• Patient-Centered, Real-World Design
  Trials designed around reduced site visits, community-based testing, and adherence support, maximizing retention while maintaining scientific robustness.
• Collaborative Clinical Network
  Strategic alliances with nephrology associations, dialysis programs, and transplant centers across Nigeria, Ghana, Kenya, and South Africa, creating a harmonized ecosystem for regional kidney-health innovation.

We help sponsors and investigators access well-characterized renal populations, leverage digital data systems for high-quality endpoints, and deliver globally credible kidney-health research rooted in African expertise. By combining scientific precision with human-centered design, Xcene Research is accelerating the discovery of therapies that improve outcomes for patients living with kidney disease across Africa.

Accelerating Chronic Disease Innovation

Xcene Research is advancing metabolic and endocrine research through a coordinated network of over 10 endocrinology and internal medicine research centers across Sub-Saharan Africa. Our integrated ecosystem brings together physicians, nutritionists, diabetologists, and behavioral scientists to address the growing burden of chronic metabolic diseases such as type 2 diabetes, obesity, metabolic syndrome, thyroid disorders, and dyslipidemia.

Our Metabolic Therapeutic Network leverages deep clinical expertise, digital health integration, and real-world data collection to design and execute trials that not only meet regulatory and scientific rigor but also reflect the lived experiences of diverse populations. By combining evidence-based medicine with culturally sensitive approaches, we accelerate the discovery and validation of new therapies that improve metabolic health outcomes across Africa and beyond.

Our expertise covers:

• Interventional and Observational Trials
  End-to-end clinical trial support for pharmacologic and non-pharmacologic interventions targeting glycemic control, lipid regulation, and weight management, including GLP-1 receptor agonists, SGLT2 inhibitors, and novel metabolic pathway modulators.
• Digital Biomarker and Continuous Monitoring Integration
  Use of wearable devices, continuous glucose monitoring (CGM), and remote blood pressure tracking to enable longitudinal data capture and real-time clinical decision-making through mobile health (mHealth) platforms.
• Behavioral and Lifestyle Intervention Studies
  Development and deployment of evidence-based lifestyle modification programs integrating nutrition, physical activity, and behavioral therapy modules tailored to local populations for sustained adherence and metabolic improvement.
• Real-World Evidence (RWE) and Health Outcomes Research
  Implementation of long-term cohort and post-marketing studies that generate insights into treatment durability, adherence, and cost-effectiveness within African populations.
• XP Recruiter for Patient-Matching and Retention
  Proprietary patient recruitment engine enabling rapid identification and matching of eligible participants based on electronic health data, social determinants, and behavioral profiling — with digital retention support throughout trial duration.

Our Differentiation

• Chronic Disease Cohort Expertise
  Demonstrated capacity to recruit, manage, and retain large chronic disease populations, ensuring sustained engagement and data integrity over multi-year studies.
• Regulatory and Operational Excellence
  Seamless management of multi-country protocols and submissions, harmonized with regional ethics boards and regulatory authorities to ensure efficiency and compliance.
• Data-Driven, Human-Centered Research
  Integration of EHR data, digital endpoints, and socio-behavioral insights to produce high-quality evidence that reflects both biological and contextual factors influencing metabolic health.

We advance metabolic and endocrine research with agility, empathy, and scientific precision transforming chronic disease management through innovation that is inclusive, data-driven, and locally relevant. By bridging global standards with African clinical realities, Xcene Research empowers sponsors and investigators to deliver therapies that truly change lives.

Conducting High-Impact Studies in HIV, TB, Malaria, and Emerging Pathogens

Infectious diseases continue to account for a significant share of morbidity and mortality across Sub-Saharan Africa, where HIV, tuberculosis (TB), malaria, and viral hepatitis remain public health priorities and emerging pathogens (such as Ebola, Lassa fever, and SARS-CoV-2) pose ongoing threats to health security.

Xcene Research is at the forefront of advancing infectious disease research across the continent. Through our Infectious Disease Therapeutic Network, we empower global sponsors, development partners, and public health institutions to design and implement therapeutic, prophylactic, diagnostic, and epidemiologic studies that are both scientifically rigorous and socially grounded.

Our approach combines cutting-edge laboratory science, precision trial execution, and strong community partnerships ensuring that studies are conducted ethically, efficiently, and with deep local engagement.

Capabilities

• Comprehensive Clinical Trial Execution (Phase II–IV)
  Full-service management of interventional and observational infectious disease trials, including antiviral, antimicrobial, vaccine, and immunotherapy agents. Expertise spans dose optimization, pharmacokinetics, resistance analysis, and real-world effectiveness evaluations.
• HIV Prevention, Treatment, and Long-Acting Therapeutics
  Broad experience in HIV clinical development, including trials on PrEP, long-acting injectables, integrase inhibitors, monoclonal antibodies, and immune-based therapies. Capacity for both adult and adolescent cohorts, integrating digital adherence tools and retention tracking.
• Tuberculosis (TB) Clinical and Diagnostic Research
  Execution of drug-susceptible and multi-drug-resistant TB trials, evaluating combination regimens, biomarkers of treatment response, and new diagnostic algorithms. Laboratory infrastructure supports GeneXpert, MGIT, and next-generation sequencing (NGS) for resistance profiling and surveillance.
• Malaria Therapeutics, Vaccines, and Vector Control
  End-to-end study delivery for antimalarial drug trials, prophylactic interventions, and vaccine programs, including RTS,S and R21 platforms, alongside community-based vector-control and epidemiologic surveillance studies.
• Emerging and Re-Emerging Pathogen Research
  Rapid-response capability for outbreak studies, epidemiologic surveillance, diagnostic validation, and therapeutic evaluation of novel pathogens (including Lassa fever, Ebola, and COVID-19).
• Molecular Surveillance, Biobanking, and Resistance Monitoring
  Integration of biobanking systems for sample preservation and long-term pathogen tracking, coupled with advanced laboratory pipelines for PCR, ELISA, sequencing, and antigenic drift analysis, enabling genomic and phenotypic surveillance.
• Health Systems and Implementation Research
  Execution of operational and implementation studies evaluating diagnostic uptake, treatment adherence, and health-system resilience generating real-world evidence that informs policy and practice across Africa.

Our Differentiation

• Pan-African Infectious Disease Network
  Proven multi-country operational footprint encompassing high-burden and resource-limited settings, with harmonized regulatory, ethical, and quality assurance frameworks.
• Advanced Laboratory and Data Integration
  Seamless linkage between clinical sites, molecular labs, and data management systems, enabling high-throughput sample processing, electronic data capture (EDC), and near real-time analytics.
• Community and Stakeholder Partnerships
  Deep collaborations with community advisory boards (CABs), NGOs, and public health authorities to build trust, enhance enrollment, and sustain participant engagement vital for long-duration or stigma-sensitive studies.
• Regulatory and Logistical Expertise
  Experience in navigating multi-country regulatory submissions, importation requirements, and biosafety logistics for infectious agents and investigational products.
• Digital Health and Decentralized Research Models
  Integration of Genescor, our telehealth and patient-engagement platform, to enable remote monitoring, adherence support, and decentralized follow-up, particularly in hard-to-reach populations.

Xcene Research delivers infectious disease studies with scientific precision, operational resilience, and community empathy ensuring that the data generated across Africa drives global solutions for prevention, treatment, and control.

By merging molecular science with human insight, we are helping shape the future of infectious disease innovation, strengthening surveillance capacity, and advancing equitable access to life-saving interventions across the continent.

Contact Us

Championing Clinical Research that Prioritizes Women’s Well-Being

Women’s health is the foundation of population health, influencing every aspect of societal stability, child health, and community development. Yet, globally and particularly across Sub-Saharan Africa women remain underrepresented in clinical research, and many conditions affecting them are underdiagnosed or undertreated.

At Xcene Research, we are redefining women’s health research by ensuring that clinical trials are scientifically rigorous, socially responsive, and inclusive of women across all life stages from adolescence and reproductive years through menopause and aging. Our Women’s Health Therapeutic Network connects experts in obstetrics, gynecology, endocrinology, and reproductive medicine with digital and community-driven frameworks to deliver studies that advance innovation while respecting local context and culture.

Capabilities

• Comprehensive Women’s Health Clinical Trials (Phase I–IV)
  Design and execution of interventional and observational studies spanning contraception, fertility, menopause, pregnancy, and post-partum health, including hormonal and non-hormonal therapies, devices, and combination interventions.
• Reproductive and Endocrine Research
  Trials investigating polycystic ovarian syndrome (PCOS), endometriosis, menstrual disorders, infertility, and perimenopausal syndromes, as well as metabolic and hormonal interplay affecting cardiovascular, bone, and mental health in women.
• Maternal and Perinatal Health Studies
  Multi-site collaborations with tertiary hospitals and teaching centers conducting trials in maternal-fetal medicine, gestational diabetes, hypertensive disorders, preterm birth prevention, and maternal vaccine programs.
• Integrated Clinical and Laboratory Support
  End-to-end integration with central laboratories for hormonal profiling, genetic testing, and biomarker discovery related to fertility, endocrine function, and reproductive immunology.
• Digital Recruitment and Retention Solutions
  Use of XP Recruiter for identifying eligible participants across diverse demographics, coupled with Genescor-enabled mobile engagement for follow-up, adherence tracking, and education empowering women through informed participation.
• Socio-Behavioral and Implementation Research
  Execution of community and behavioral studies focused on reproductive decision-making, health-seeking behavior, gender-based barriers, and the social determinants of women’s health outcomes.

Our Differentiation

• Inclusive, Gender-Sensitive Trial Design
  Culturally adapted study designs minimizing visit burden, ensuring reproductive safety, and incorporating flexible consent frameworks suitable for women in varying family, occupational, and cultural contexts.
• Regional Expertise in Maternal and Perinatal Trials
  Active collaborations with leading maternal and child health centers across Nigeria, Ghana, Kenya, and Rwanda, enabling access to large obstetric cohorts and real-world maternal health data.
• Interdisciplinary Clinical Network
  Cross-specialty teams integrating OB/GYN specialists, endocrinologists, pediatricians, behavioral scientists, and biostatisticians to ensure comprehensive evaluation of interventions affecting women’s wellness.
• Multilingual Education and Telehealth Support
  Multilingual patient education materials and teleconsultation models ensuring comprehension, trust, and continuity of care particularly for long-duration or postnatal studies.
• Advancing Equity in Clinical Science
  Strong commitment to closing the gender gap in research through capacity-building, mentorship, and equitable participation of women as investigators, coordinators, and decision-makers across the Xcene network.

We advance women’s health research with scientific precision, empathy, and inclusion, ensuring that every trial contributes to better health outcomes and equitable access for women worldwide.

By combining rigorous science with cultural intelligence, Xcene Research enables sponsors and investigators to generate data that reflect the full spectrum of women’s experiences driving new standards in reproductive, maternal, and hormonal health research across Africa and the world.

Evaluating Therapies for Chronic and Acute Pain Conditions

Pain is a universal human experience and one of the most under-treated yet most complex conditions in medicine. Across Africa, pain often remains poorly managed due to limited access to specialized care, inadequate understanding of chronic pain mechanisms, and sociocultural barriers to reporting and treatment.

Xcene Research is closing this gap by conducting high-quality pain-management clinical trials that evaluate both pharmacologic and non-pharmacologic interventions for acute, chronic, and neuropathic pain across diverse populations. Our goal is to generate robust, patient-centered data that advance therapeutic innovation and improve quality of life for individuals living with pain from post-surgical recovery to chronic diseases such as sickle cell disease, diabetes, and arthritis.

Capabilities

• Comprehensive Clinical Trial Management (Phase I–IV)
  Design and execution of interventional and observational studies evaluating analgesics, opioids, non-opioid agents, cannabinoids, neuromodulators, biologics, and complementary pain therapies.
• Targeted Pain Indication Expertise
  Experience across a wide spectrum of pain conditions including postoperative pain, musculoskeletal pain, diabetic neuropathy, cancer-related pain, migraine, and sickle cell pain crises. Trials are designed with both acute endpoints (e.g., time-to-relief, pain intensity) and chronic measures (e.g., functional outcomes, psychological adaptation).
• Validated Pain Assessment Methodologies
  Utilization of standardized pain measurement tools such as Visual Analog Scale (VAS), Numeric Rating Scale (NRS), Brief Pain Inventory (BPI), and McGill Pain Questionnaire, combined with patient-reported outcome measures (PROMs) to capture holistic treatment effects.
• Digital and Physiologic Monitoring
  Integration of wearable sensors, digital diaries, and ePRO (electronic patient-reported outcomes) platforms to track pain fluctuations, sleep quality, and physical activity in real time. These technologies improve adherence, data reliability, and long-term follow-up.
• Multimodal and Behavioral Pain Studies
  Clinical evaluations of rehabilitation protocols, cognitive behavioral therapy (CBT), mindfulness-based stress reduction, and physiotherapy, designed as adjuncts or comparators to pharmacologic treatment.
• Pharmacovigilance and Safety Oversight
  Continuous monitoring for tolerance, dependence, and adverse events through validated pharmacovigilance systems aligned with ICH-GCP, WHO, and FDA guidelines.

Our Differentiation

• Access to Multidisciplinary Pain Networks

Collaboration with pain clinics, anesthesiologists, neurologists, physiotherapists, and palliative care specialists, ensuring comprehensive evaluation across biological, psychological, and social dimensions of pain.

• Culturally Sensitive Pain Assessment
  Expertise in adapting pain measurement frameworks to local languages and cultural contexts, addressing underreporting tendencies and ensuring accurate data representation.
• Regulatory Experience in Pain Therapeutics
  Proven track record conducting opioid, non-opioid, cannabinoid, and device-based pain trials, with full compliance to national drug control, ethics, and importation standards.
• Longitudinal Patient Engagement and Retention
  Sustainable retention models for chronic pain cohorts through Genescor-enabled follow-up, patient education, teleconsultations, and caregiver inclusion — supporting both short- and long-term endpoint collection.
• Integration with Disease-Specific Networks
  Alignment with Xcene’s Hematology, Metabolic, and Neurology therapeutic networks for cross-disciplinary pain studies (e.g., sickle cell vaso-occlusive pain, diabetic neuropathy, post-stroke pain syndromes).

We combine scientific rigor, digital innovation, and human empathy to transform how pain is studied and managed. Through our integrated ecosystem linking clinical sites, digital tools, and community partnerships. Xcene Research delivers high-quality data that accelerate the development of therapies relieving pain, restoring function, and improving quality of life across Africa and beyond.

Innovating with Care: Clinical Research for the Youngest Patients

Children represent nearly 40% of Africa’s population, and pediatric clinical research remains underdeveloped across the continent. The scarcity of age-appropriate data limits access to safe and effective therapies for conditions ranging from infectious diseases and hematologic disorders to metabolic and genetic conditions.

Xcene Research is transforming this landscape through its Pediatric Therapeutic Network, a coordinated ecosystem of 25+ pediatricians, neonatologists, and child-health investigators working across dedicated pediatric and neonatal trial sites. Every study we conduct is grounded in safety, ethics, and empathy, ensuring that innovation in children’s medicine reflects both scientific rigor and human care.

Capabilities

• Comprehensive Pediatric and Neonatal Trials (Phase I–IV)
  Full-service execution of interventional and observational studies in hematology, infectious diseases, metabolic disorders, vaccines, and rare pediatric conditions. Expertise in dose-finding, pharmacokinetics/pharmacodynamics (PK/PD), and safety assessments for age-stratified cohorts.
• Formulation and Dosing Optimization
  Development and testing of pediatric-specific formulations (liquid, dispersible, chewable, and micro-dosed forms) with adaptive study designs that accommodate weight, age, and developmental differences.
• Age-Appropriate Consent and Engagement
  Implementation of child-friendly assent and caregiver consent models, complemented by culturally sensitive communication materials to ensure comprehension and trust.
• Digital Recruitment and Matching
  Use of XP Recruiter to identify eligible pediatric participants and match caregivers through hospital databases, immunization programs, and community health networks — improving recruitment speed and diversity.
• Remote and Decentralized Data Capture
  Integration of Genescor-enabled digital data collection, mobile follow-up, and teleconsultations to facilitate safe participation, especially for children in remote or resource-limited settings.
• Longitudinal and Real-World Pediatric Studies
  Management of long-term follow-up and registry studies for chronic pediatric conditions such as sickle-cell disease, asthma, epilepsy, and developmental disorders generating valuable real-world evidence (RWE).

Our Differentiation

• Strong Ethical and Regulatory Oversight
  Adherence to ICH-E11 (Clinical Investigation of Medicinal Products in the Pediatric Population), local ethics frameworks, and global pediatric safety standards, ensuring the highest level of child protection.
• Specialized Pediatric Investigators and Nurses
  Network of pediatricians, neonatologists, and pediatric nurses trained in clinical research protocols, child communication, and emergency preparedness across major teaching hospitals.
• Family-Centered Trial Operations
  Study environments designed for comfort and support — including family waiting areas, child-friendly sampling processes, and caregiver counseling to minimize stress and improve compliance.
• Retention Through Compassionate Care
  Proven ability to maintain long-term engagement in pediatric trials through personalized follow-ups, caregiver education, and community-based health reinforcement.
• Integration with Broader Therapeutic Programs
  Seamless collaboration with Vaccine, Hematology, and Metabolic networks for cross-disciplinary pediatric research — from early diagnosis to prevention and chronic care management.

We conduct pediatric research that is safe, compassionate, and transformative — shaping the future of healthcare for children across Africa.

By combining scientific excellence, ethical responsibility, and digital innovation, Xcene Research empowers sponsors and investigators to generate high-quality pediatric data that drive equitable global health outcomes.

Contact Us

Leading Research on Diverse African Skin Populations

Africa is home to some of the most genetically and phenotypically diverse skin types in the world, yet African skin remains significantly underrepresented in global dermatologic research and product development. This underrepresentation affects how dermatologic drugs, biologics, and devices are developed, validated, and prescribed for patients of color.

Xcene Research is transforming this landscape by leading dermatology clinical studies that investigate skin physiology, pigmentation pathways, immunologic mechanisms, and pharmacologic responses unique to African populations. Our Dermatology Therapeutic Network connects dermatologists, immunologists, pathologists, and cosmetic science experts across the continent to generate high-quality data that inform global standards of safety, efficacy, and inclusion in skin health innovation.

Capabilities

• Clinical Trials Across Dermatologic Indications
  Design and execution of Phase I–IV trials targeting acne, eczema, psoriasis, atopic dermatitis, vitiligo, fungal infections, alopecia, and pigmentation disorders, as well as investigational therapies for autoimmune and inflammatory skin diseases.
• Evaluation of Topical, Systemic, and Biologic Therapies
  Trials assessing topical formulations, oral/systemic agents, and biologics (including monoclonal antibodies and JAK inhibitors) to evaluate treatment response and safety across different Fitzpatrick skin phototypes (IV–VI).
• Advanced Imaging and Diagnostic Capabilities
  Access to digital dermoscopy, confocal microscopy, and multispectral imaging for objective lesion assessment. Integration with histopathology, immunohistochemistry, and molecular profiling supports robust endpoint verification.
• Pigmentation, Barrier, and Inflammation Research
  Specialized studies exploring melanogenesis, transepidermal water loss (TEWL), sebaceous gland physiology, and immune signaling in skin of color contributing to precision dermatology and pharmacogenomic insights.
• Patient Registries and Real-World Data (RWD)
  Establishment of longitudinal dermatology registries capturing epidemiologic trends, treatment outcomes, and adverse event data across multiple African countries, enhancing real-world evidence generation.
• Digital Recruitment and Monitoring Tools
  Use of XP Recruiter to identify and engage participants based on phenotype, condition, and treatment history; coupled with ePRO and mobile photo documentation to monitor response in remote or outpatient settings.
• Dermatocosmetic and Device Validation Studies
  Evaluation of cosmeceutical and dermatologic devices (e.g., laser, phototherapy, wearables) for tolerance, efficacy, and safety in melanin-rich skin generating data to guide global manufacturers and formulators.

Our Differentiation

• Pan-African Dermatology Research Network
  Extensive investigator base spanning academic hospitals, cosmetic research centers, and specialized dermatology clinics, with harmonized study procedures and centralized data management.
• Expertise in Melanin Biology and Immunodermatology
  Advanced scientific understanding of melanocyte biology, inflammatory pathways, and skin barrier integrity specific to African skin, supporting pharmacodynamic and mechanistic studies.
• Strong Partnerships and Advocacy Integration
  Collaboration with dermatologic societies, pigmentary disorder foundations, and patient associations to promote recruitment diversity, awareness, and trial literacy.
• Culturally Sensitive and Ethical Research Framework
  Commitment to inclusive trial design that respects cultural perceptions of skin conditions, beauty, and self-image, enhancing participant trust and adherence.
• Data That Shapes Global Dermatologic Innovation
  By generating representative datasets, Xcene Research ensures that emerging dermatologic and cosmetic therapies are validated across all skin types, advancing global equity in skin health innovation.

We bring representation, scientific accuracy, and cultural intelligence to dermatology research ensuring that every molecule, biologic, and device is tested and optimized for diverse African skin populations.

Through our integrated network of dermatologists, pathologists, and translational scientists, Xcene Research is driving the inclusion of African data in global regulatory submissions, paving the way for therapies that truly reflect the world’s full spectrum of skin diversity.

Advancing Safety, Performance, and Innovation in Medical Technology

The rapid growth of medical technology across Africa presents unprecedented opportunities to improve diagnosis, treatment, and monitoring. Device validation, usability, and regulatory harmonization remain major priorities for global and local innovators.

Xcene Research bridges this gap by providing end-to-end support for medical device evaluation, encompassing diagnostics, imaging systems, digital wearables, implantables, and therapeutic devices. Through our Medical Device Research and Validation Network, we deliver scientifically rigorous, ethically compliant, and operationally efficient studies that align with ISO 14155, FDA, EMA, and African regulatory frameworks.

Our integrated ecosystem brings together engineers, clinicians, biostatisticians, usability specialists, and regulatory experts, ensuring every study meets both global performance standards and Africa’s unique clinical realities.

Capabilities

• Clinical Evaluation and Validation (Class I–III Devices)
  Design and execution of first-in-human, feasibility, pivotal, and post-market clinical follow-up (PMCF) studies for medical and in-vitro diagnostic (IVD) devices. Expertise includes cardiac monitoring systems, imaging modalities, point-of-care diagnostics, orthopedics, and digital therapeutics.
• Usability and Human-Factors Engineering
  Assessment of device ergonomics, interface design, and user behavior through structured usability and human-factors studies, ensuring alignment with IEC 62366-1 and FDA guidance on usability validation.
• Biocompatibility, Safety, and Performance Testing
  Collaboration with accredited laboratories for biocompatibility, electrical safety, mechanical stress, sterilization, and electromagnetic compatibility (EMC) testing. Integration of risk management (ISO 14971) and post-market safety surveillance across the product lifecycle.
• Integration with Laboratory and Clinical Systems
  Advanced connectivity for IVD validation, sample handling, and assay correlation, including molecular, serologic, and digital pathology platforms. Our central laboratories provide precision analytics, calibration, and data harmonization for diagnostic device trials.
• Digital Health and AI-Based Device Studies
  Expertise in wearables, digital biomarkers, telemedicine hardware, and AI-driven diagnostics focusing on algorithm validation, real-world data collection, and model generalizability across African populations.
• Regulatory and Quality Compliance Support
  End-to-end documentation and submissions aligned with ISO 14155, ISO 13485, MDR 2017/745, FDA 21 CFR Part 812, and African Medicines Agency (AMA) emerging device frameworks.
• Post-Market Surveillance and Health Technology Assessment (HTA)
  Longitudinal tracking of safety and performance metrics through real-world evidence (RWE) and post-market registries, including cost-effectiveness and implementation impact assessments for healthcare systems.

Our Differentiation

• Multidisciplinary Scientific and Engineering Expertise
  Cross-functional collaboration among biomedical engineers, clinicians, human-factors scientists, and regulatory specialists, ensuring a full-spectrum approach from design validation to field deployment.
• Access to Diverse Real-World Populations
  Multi-country site network with access to urban hospitals, community clinics, and specialty centers, enabling robust device performance validation across diverse physiological, genetic, and environmental contexts.
• Digital and Data Management Integration
  Centralized, audit-ready systems for data acquisition, quality control, and electronic case report forms (eCRFs) compliant with GCP, GDPR, and ISO 27001 data standards.
• Proven Experience in Emerging Technologies
  Demonstrated success in evaluating AI-based imaging tools, connected wearables, biosensors, and hybrid digital-therapeutic systems through partnerships with global innovators and African technology start-ups.
• Accelerated Regulatory Pathways and Local Insight
  Deep engagement with African regulatory authorities, standards organizations, and ethics boards, enabling faster approvals and contextually relevant safety reporting frameworks.

We advance medical device and technology research that merges engineering precision with clinical insight, driving innovation that strengthens Africa’s healthcare systems and contributes to global regulatory science.

By combining rigorous validation, usability optimization, and real-world implementation, Xcene Research ensures that emerging technologies are safe, effective, and accessible shaping the next generation of diagnostics, therapeutics, and digital health solutions for Africa and beyond.

Contact Us